William Ho, M.D., Ph.D.
About William Ho, M.D., Ph.D.
Company
William Ho currently serves as the Chief Medical Officer at RAPT Therapeutics, a role he has held since 2015. RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Under his leadership, the company focuses on advancing its clinical pipeline and leveraging its scientific expertise to develop innovative treatments.
Title
William Ho holds the position of Chief Medical Officer at RAPT Therapeutics. His extensive experience in clinical development and leadership roles in the biopharmaceutical industry makes him a pivotal figure in driving the company's medical strategies and overseeing the progression of its clinical programs.
Education and Expertise
William Ho received an A.B. in Molecular Biology from Princeton University. He subsequently earned both an M.D. and a Ph.D. in Microbiology and Immunology from Stanford University School of Medicine, where he studied cellular immunology in the laboratory of Mark Davis, Ph.D. His medical training includes completing an internship and residency in Internal Medicine at the University of California, San Francisco. Furthering his expertise, he received training in Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy methods to treat leukemia.
Background
Before joining RAPT Therapeutics, William Ho served as Vice President of Clinical Development at Igenica Biotherapeutics. Prior to this, he worked for seven years at Genentech in the Exploratory Clinical Development (BioOncology) group, where he was a Senior Medical Director. During his tenure at Genentech, he led the development of multiple small molecule, antibody, and antibody-drug conjugate programs from IND filing to Phase III. His notable contributions include involvement in the clinical development of Gazyva (obinutuzumab), Venclexta (venetoclax), and Polivy (polatuzumab vedotin-piiq).